Celltrion Pharm셀트리온제약

Celltrion Pharm's trailing profits remain positive, but the share price has fallen about 35% over the past year and sits near its 52-week low.

Trailing twelve-month revenue to H1 2026 is ₩578B with a 10.7% operating margin and ₩41B of net income, up from 2024 and 2025 levels on revenue. The stock trades at ₩36,500, well below its 52-week high of ₩78,300, and the company announced a partial recall of its Ganejin product on October 22, 2026.

What stands out

• Revenue grew 12.3% in 2025 to ₩536B, and trailing revenue to H1 2026 reached ₩578B, indicating continued top-line growth.
• Operating margin was 10.7% on a trailing basis versus 10.5% in 2025 and 7.8% in 2024, while net margin is 7.2%.
• Net debt position is not clear from the data: cash is ₩52B against borrowings of ₩142B, and liabilities are 73.5% of equity.
• The DCF base fair value is ₩16,979 against a ₩36,500 close, while the bear and bull cases are ₩8,717 and ₩31,520; the data does not explain the model's assumptions beyond a 7.1% rate.
• Foreign ownership is 5.2%, little changed over 60 days, while institutions net sold about ₩7.6B over the last 20 days.

What to watch

• The partial recall of Ganejin reported on October 22, 2026; the data does not state its scale or financial impact.
• Next quarterly or annual results and any further filings, since the latest data covers H1 2026 and the half-year report was filed August 14, 2026.
• Heavy reliance on parent Celltrion for exclusive domestic sales rights to 12 biopharmaceutical products, as named in the company profile.